Prognyx oncology intelligence
Live ClinicalTrials.gov oncology trial comparison around an asset, plus landscapes and CI briefings.
¿Debería usar esto?
Calidad y seguridad
Basado en el análisis automatizado de las definiciones de herramientas y el cumplimiento del protocolo.
Costo de contexto
Este es el número aproximado de tokens que se consumen cada vez que las herramientas del servidor se cargan en el contexto de un modelo. Los recuentos más altos reducen la atención disponible para otras tareas.
Instalar
Instalación con un clic
Agrega esto a tu archivo `claude_desktop_config.json`:
{
"mcpServers": {
"oncology-intelligence": {
"url": "https://www.prognyx.com/api/mcp"
}
}
}Puntos de conexión remotos
https://www.prognyx.com/api/mcpstreamable-httpQué puede hacer
Inventario de herramientas
Herramientas (3)
🟢compare_trials(asset, indication)
Up to three interventional ClinicalTrials.gov studies matching an asset or target AND an oncology indication, side by side: sponsor, phase, status, declared arms, primary outcomes, last update, registry URL. Active studies first, then later phase; different sponsors where possible. Use a target (e.g. "KIF18A", "B7-H3") rather than one drug name to see other programmes.
Esquema de entrada
{
"type": "object",
"properties": {
"asset": {
"type": "string",
"maxLength": 80,
"description": "Public asset or target, e.g. \"sotorasib\", \"KRAS G12C\", \"B7-H3\"."
},
"indication": {
"type": "string",
"maxLength": 80,
"description": "Oncology indication, e.g. \"colorectal cancer\", \"NSCLC\"."
}
},
"required": [
"asset",
"indication"
],
"additionalProperties": false
}🟢search_registry(query, limit)
Live landscape for a target, asset, company, indication or NCT number: total and active study counts, leading sponsors, phase mix, the most recently updated studies with URLs, and related Prognyx briefings. Counts for phases and sponsors come from a recent sample, stated in the result.
Esquema de entrada
{
"type": "object",
"properties": {
"query": {
"type": "string",
"maxLength": 160,
"description": "e.g. \"KRAS G12C\", \"Nuvalent\", \"claudin 18.2 gastric cancer\", \"NCT05132075\"."
},
"limit": {
"type": "integer",
"minimum": 1,
"maximum": 25,
"default": 10,
"description": "Studies to return."
}
},
"required": [
"query"
],
"additionalProperties": false
}🟢search_briefings(query, limit)
Prognyx oncology competitive-intelligence briefings (each claim linked to a primary source) matching a drug, company, target or indication, newest first, with URL, date and summary.
Esquema de entrada
{
"type": "object",
"properties": {
"query": {
"type": "string",
"maxLength": 120,
"description": "Drug, company, target or indication. Empty returns the latest."
},
"limit": {
"type": "integer",
"minimum": 1,
"maximum": 20,
"default": 5,
"description": "Briefings to return."
}
},
"additionalProperties": false
}Comunidad
Evidencia